Our approach using “half-and-half” combination of DA and EPO may be a safe and easy way to introduce DA without overshooting Hb levels beyond the ranges recommended.19,20 In the study for comparing DA with EPO on anemia management in patients with chronic renal failure not yet on dialysis reported by the European/Australian Novel Erythropoiesis Stimulating Protein Study Group,7 Hb overshooting >14 g/dL developed in 24% of patients treated with DA and in 35% of patients treated with EPO. The gene discussed is GSTM1; the disease is chronic kidney disease.